Predictive Oncology Inc. (NASDAQ:POAI – Get Rating) shares crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.66 and traded as low as $0.42. Predictive Oncology shares last traded at $0.44, with a volume of 238,105 shares trading hands.
Predictive Oncology Stock Performance
The stock’s 50-day moving average is $0.41 and its 200 day moving average is $0.66. The firm has a market cap of $29.11 million, a P/E ratio of -1.42 and a beta of 1.35.
Predictive Oncology (NASDAQ:POAI – Get Rating) last released its quarterly earnings data on Thursday, May 12th. The medical instruments supplier reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). Predictive Oncology had a negative net margin of 1,314.56% and a negative return on equity of 27.33%. The firm had revenue of $0.32 million during the quarter, compared to the consensus estimate of $1.00 million. On average, research analysts anticipate that Predictive Oncology Inc. will post -0.06 EPS for the current year.
Insider Activity at Predictive Oncology
Hedge Funds Weigh In On Predictive Oncology
Several hedge funds have recently modified their holdings of POAI. Charles Schwab Investment Management Inc. bought a new position in shares of Predictive Oncology in the 1st quarter valued at about $54,000. RB Capital Management LLC bought a new position in shares of Predictive Oncology in the 2nd quarter valued at about $65,000. Finally, Virtu Financial LLC bought a new position in shares of Predictive Oncology in the 1st quarter valued at about $66,000. Institutional investors own 6.23% of the company’s stock.
Predictive Oncology Company Profile
Predictive Oncology Inc, a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation.
- Get a free copy of the StockNews.com research report on Predictive Oncology (POAI)
- Is Starbucks Shooting For The Moon?
- PayPal Continues To Struggle As Competition Increases
- Two High-Yield Deep-Values You Shouldn’t Ignore
- AutoNation Stock is Firing on All Pistons
- Proposed Tesla Stock Split Drives EV Market Higher
Receive News & Ratings for Predictive Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Predictive Oncology and related companies with MarketBeat.com's FREE daily email newsletter.